Clinical Trials
8
Active:1
Completed:5
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (50.0%)Phase 3
3 (37.5%)Phase 2
1 (12.5%)A Phase I Clinical Trial to Evaluate CU-10101 Unguent
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT06744569
- Locations
- 🇨🇳
Shanghai Skin Disease Hospital, Shanghai, Shanghai, China
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101)
Phase 3
Active, not recruiting
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: CU-20101 treatment for Moderate to Severe Glabellar Striae
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 554
- Registration Number
- NCT06585696
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Phase 2 Clinical Study of CU-20401
Phase 2
Completed
- Conditions
- Efficacy and Safety
- Interventions
- Drug: Subcutaneous injection of CU-20401
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT06194188
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 286
- Registration Number
- NCT05793892
- Locations
- 🇨🇳
Shanghai Ninth People Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Tsinghua Changgung Hospital, Beijing, China
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT05380427
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou, China
- Prev
- 1
- 2
- Next
News
No news found